Computational analysis of the binding affinities of the natural-product cyclopentapeptides argifin and argadin to chitinase B from Serratia marcescens

Bioorganic & Medicinal Chemistry
2008.0

Abstract

Molecular dynamics (MD) simulations and the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method were applied to study the interaction of the natural-product cyclopentapeptide chitinase inhibitors argifin and argadin with chitinase B (ChiB) from Serratia marcescens. Argadin inhibited ChiB with an inhibition constant (K(i)) value of 20 nM, which was three orders of magnitude greater than that of argifin (K(i)=33,000 nM). The MM-PBSA free-energy analysis provided absolute binding free energies of -6.98 and -11.16 kcal/mol for the argifin and argadin complexes, respectively. These estimates were in good agreement with the free energies derived from the experimental K(i) values (-6.36 and -10.92 kcal/mol for the argifin and argadin complexes, respectively). The energetic analysis revealed that the van der Waals and nonpolar solvation energies drove the binding of both argifin and argadin. We found that the binding of argadin gained approximately 12 kcal/mol more van der Waals energy than that of argifin, which was mainly responsible for the difference in binding free energy between argifin and argadin. In particular, W220 and W403 of ChiB were found to contribute to the more favorable van der Waals interaction with argadin. We also designed argifin derivatives with better binding affinity, in which a constituent amino-acid residue of argifin was mutated to one with a bulky side chain. The derivative in which D-Ala of argifin was replaced with D-Trp appeared to possess a binding affinity that was equally potent to that of argadin.

Knowledge Graph

Similar Paper

Computational analysis of the binding affinities of the natural-product cyclopentapeptides argifin and argadin to chitinase B from Serratia marcescens
Bioorganic & Medicinal Chemistry 2008.0
NMR spectroscopy and computational analysis of interaction between Serratia marcescens chitinase B and a dipeptide derived from natural-product cyclopentapeptide chitinase inhibitor argifin
Bioorganic & Medicinal Chemistry 2010.0
Computer-aided rational molecular design of argifin-derivatives with increased inhibitory activity against chitinase B from Serratia marcescens
Bioorganic & Medicinal Chemistry Letters 2009.0
Molecular modeling of human acidic mammalian chitinase in complex with the natural-product cyclopentapeptide chitinase inhibitor argifin
Bioorganic & Medicinal Chemistry 2009.0
An efficient synthesis of argifin: A natural product chitinase inhibitor with chemotherapeutic potential
Bioorganic & Medicinal Chemistry Letters 2005.0
Creation of Customized Bioactivity within a 14-Membered Macrolide Scaffold: Design, Synthesis, and Biological Evaluation Using a Family-18 Chitinase
Journal of Medicinal Chemistry 2015.0
Argifin; efficient solid phase total synthesis and evalution of analogues of acyclic peptide
Bioorganic & Medicinal Chemistry 2009.0
Structure-Based Exploration of Cyclic Dipeptide Chitinase Inhibitors
Journal of Medicinal Chemistry 2004.0
Argifin, a New Chitinase Inhibitor, Produced by Gliocladium sp. FTD-0668. II. Isolation, Physico-chemical Properties, and Structure Elucidation.
The Journal of Antibiotics 2000.0
Molecular Dynamics Simulations of the TEM-1 β-Lactamase Complexed with Cephalothin
Journal of Medicinal Chemistry 2005.0